OmniAb Investor Presentation Deck

Q1 2023 and Recent Updates SELECT RECENT DEVELOPMENTS SHOW CONTINUED PARTNER MOMENTUM FcRn ● Batoclimab ● ● HANALL HARBOUR BIOMED Ongoing studies in: BIOPHARMA . Myasthenia Gravis (P3) Thyroid Eye Disease (P3) Chronic Inflammatory IMMUNOVANT Reference: Partner and Company disclosures Demyelinating Polyneuropathy (P2b) Graves' Disease (P2) FcRn ● ● IMVT-1402 HANALL IMMUNOVANT BIOPHARMA Next-gen FcRn antagonist Immunovant expects SAD/MAD Phase 1 data in second half of 2023 CD228x4-1BB ● SGN-BB228 ● Seagen An investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB directed Anticalins Seagen announced Phase 1 study now enrolling in advanced melanoma and other solid tumors 10 OmniAb

View entire presentation